Bezuclastinib and Sunitinib for Gastrointestinal Stromal Tumors

PEAK Phase 3 already reported positive topline on Nov 10, 2025: mPFS 16.5 vs 9.2 mo, HR 0.50 (CI 0.39-0.65), p<0.0001, ORR 46% vs 26%. FDA Breakthrough Therapy granted, NDA submission via RTOR underway. Primary endpoint clearly met with strong statistical significance and clean safety. Resolves YES with very high probability.

Phase 3 randomized PFS endpoint is clinically meaningful, but advanced/metastatic GIST against active sunitinib is a tough bar. No prior efficacy data are provided, and primary completion is long past while still active/not recruiting, adding disclosure risk.

Phase 3 randomized Part 2 PFS endpoint in advanced GIST; bezuclastinib + sunitinib vs sunitinib alone; active not recruiting with primary completion overdue 8 months signals potential operational or data issues; standard endpoint but no prior data or population specifics to support high success odds.

The Phase 3 PEAK trial assesses bezuclastinib plus sunitinib versus sunitinib alone in GIST. The primary endpoint is progression-free survival. In Nov 2025, Cogent reported the trial met this endpoint, demonstrating a median PFS of 16.5 months for the combination versus 9.2 months for sunitinib alone (HR=0.50; p<0.0001). These definitively positive findings confirm a YES.

Phase 3 trial of bezuclastinib + sunitinib vs sunitinib in 2nd-line GIST. Sunitinib is active; adding a selective KIT inhibitor may not meaningfully improve PFS. High bar for superiority, limited prior positive Phase 2 data, and many oncology combos fail. Estimated 30% chance of positive PFS result.

Phase 3 PEAK trial of bezuclastinib+sunitinib vs sunitinib alone in 2nd-line GIST. Dual TKI combination faces additive toxicity limiting dosing. Primary completion passed 236 days ago with no positive readout signaled. Bezuclastinib's selective KIT inhibition unlikely to add meaningful PFS benefit atop sunitinib's established multi-kinase activity. High probability of negative result.

Bezuclastinib is a highly selective KIT inhibitor with strong Phase 2 data in GIST, particularly in resistant populations. The combination with sunitinib targets complementary resistance mechanisms. Given the robust prior efficacy signals and the specific focus on PFS in a randomized Phase 3 setting, the probability of meeting the primary endpoint is favorable despite general oncology trial risks.

Phase 3 study of a novel kinase inhibitor added to sunitinib in advanced GIST lacks prior efficacy data; sunitinib alone has modest PFS, and combination safety concerns may limit benefit. Historical Phase 3 success for similar combos is low, suggesting a sub‑50% chance of a positive PFS outcome.

Phase 3 GIST trial testing bezuclastinib+sunitinib vs sunitinib alone. Primary completion was Sept 2025, now 236 days past with no positive readout disclosed. GIST is a difficult indication with established TKIs; prior Phase 1/2 data for bezuclastinib was modest. Delayed disclosure beyond typical timelines raises concern of negative or borderline PFS result. Sponsor COGT has not announced topline data, suggesting potential clinical or regulatory holdup.

Phase 3 GIST trial combining bezuclastinib (selective KIT inhibitor) with sunitinib vs sunitinib alone. Hard PFS endpoint is favorable. Scientific rationale exists but sunitinib monotherapy is already effective standard of care, creating high bar. Trial past primary completion by 236 days suggests data may be maturing. Phase 3 adds conviction but competitive GIST landscape with multiple approved TKIs (imatinib, sunitinib, regorafenib, avapritinib) means incremental benefit must be substantial. Estimated ~47% YES probability given combo therapy upside balanced against efficacy ceiling of suntin